As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Announcement: COVID-19 impact on peer review
Gendelman et al. 2020
Featured Review: Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders
Jatin Machhi, …, Howard E. Gendelman
Zhang et al. 2020
Buratti et al. 2020
Featured Review: From basic research to the clinic: innovative therapies for ALS and FTD in the pipeline
Rajka Maria Liscic, …, Emanuele Buratti
Zhu et al. 2020
Featured Review: Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances
Wenzhang Wang, …, George Perry and Xiongwei Zhu
Articles
-
-
Sex-dependent calcium hyperactivity due to lysosomal-related dysfunction in astrocytes from APOE4 versus APOE3 gene targeted replacement mice
-
Divergence, Convergence, and Therapeutic Implications: A Cell Biology Perspective of C9ORF72-ALS/FTD
The Correction to this article has been published in Molecular Neurodegeneration 2020 15:37
-
Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson’s disease
-
Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders
-
Exosomal cell-to-cell transmission of alpha synuclein oligomers
-
Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1polymorphisms
-
Drosophila melanogaster as a model organism for Alzheimer’s disease
-
The SH-SY5Y cell line in Parkinson’s disease research: a systematic review
-
The Alzheimer's disease β-secretase enzyme, BACE1
Editor highlights
ICMN2020 Conference
It is with regret we announce the cancellation of the 6th International Conference on Molecular Neurodegeneration, due to the unstable situation and travel restrictions surrounding the novel Coronavirus.
Please see the ICMN website for further details.
Parkinson's disease - a series of reviews
Molecular Neurodegeneration presents a new thematic series, collating reviews on recent advances in Parkinson's Disease research.
Guest Edited by Mark Cookson and Ted Dawson, reviews will continue to publish throughout 2020. The collection can be read here.
About Us
The leading open access journal in the field of neurosciences, Molecular Neurodegeneration encompasses all aspects of neurodegeneration research at the molecular and cellular levels.
Editors-in-Chief:
- Guojun Bu, Mayo Clinic, USA
- Huaxi Xu, Sanford Burnham Prebys Medical Discovery Institute, USA
Follow
Editors-in-Chief
Guojun Bu, Mayo Clinic, USA
Huaxi Xu, Sanford Burnham Prebys Medical Discovery Institute, USA
Annual Journal Metrics
-
Speed
43 days to first decision for reviewed manuscripts only
20 days to first decision for all manuscripts
121 days from submission to acceptance
23 days from acceptance to publication
Citation Impact
8.274 - 2-year Impact Factor
8.102 - 5-year Impact Factor
1.436 - Source Normalized Impact per Paper (SNIP)
3.988 - SCImago Journal Rank (SJR)
Usage
568,061 downloads
570 Altmetric mentions
